Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Potentially better outcomes than either alone
It has been shown to help with food intolerances and gastritis , addressing digestive inflammation, including stomach ulcers , pancreatitis , as well as colitis , rectocolitis , and Crohn's disease
This guide breaks down every reason your weight loss might have stalled on tirzepatide
Freezing destroys the three-dimensional structure of peptide molecules through ice crystal formation
Triple Agonists (GLP-1/GIP/Glucagon) Titration and Tapering Algorithms At a glance Prototype agent / retatrutide (LY3437943), subcutaneous weekly injection Phase 2 peak weight loss / 24.2% at 48 weeks (12 mg cohort, N=338 total trial) Titration duration / 24 weeks across 4 dose steps before reaching maintenance Starting dose / 2 mg subcutaneous once weekly for weeks 1 to 4 Maintenance dose range / 8 mg or 12 mg once weekly depending on tolerability Primary targets / obesity, MASLD, type 2 diabetes, metabolic syndrome GI adverse events / nausea in 53 to 65% of participants at higher dose steps Taper recommendation / dose reduction over 8 to 12 weeks when discontinuing FDA status / Phase 3 (TRIUMPH program) ongoing as of early 2025
